The latest issue of the Desang Diabetes Magazine features an interview with mountaineer Jerry Gore about his diabetes kit. How do you finger-prick when hanging off a mountain in a sling? It also contains a report on the collaboration on diabetes research read more »

This month (Jan 2015) Switzerland was the first country to launch Novo Nordisk’s Xultophy (IDegLira) for people with Type 2 diabetes. Xultophy is the first combination of a basal insulin (Tresiba, insulin degludec) and a GLP-1 analogue (Victoza, liraglutide). Xultophy is administered read more »

Victoza (liraglutide) is an injectable medicine for people with type 2 diabetes. Today, as part of its Single Technology Appraisal (STA) the National Institute forHealth and Clinical Excellence (NICE) published its final guidance on the use of Victoza (liraglutide) for patients with type read more »

From a talk given at the UK launch of the new Type 2 treatment given by Viggo Birch, vice president and managing director, Novo Nordisk Ltd. In addressing a press conference held to launch Victoza a new treatment for adults with Type read more »

NICE has issued its Final Appraisal Determination (FAD) on the use of Victoza (liraglutide) for people with type 2 diabetes in the UK, the only therapy of its kind due to receive statutory funding direction. Liraglutide is a once-daily injectable human GLP-1 read more »

From a talk given by Professor Anthony Barnett (Professor of Medicine and Honorary Consultant Physician at the University of Birmingham and Heart Of England NHS Foundation Trust,Birmingham.1) at the launch of the new Type 2 treatment Victoza from Novo Nordisk held in read more »